Featured Article: Autophagic activation with Nimotuzumab enhanced chemosensitivity and radiosensitivity of esophageal squamous cell carcinoma

Experimental Biology and Medicine

Volumn 239, Issue 5, 2014, Pages 529-541

  Song, Haizhu ^a   Pan, Banzhou ^a   Yi, Jun ^a   Chen, Longbang ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Autophagy; chemotherapy; epidermal growth factor receptor; esophageal squamous cell carcinoma; radiotherapy

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; NIMOTUZUMAB; PACLITAXEL; RAPAMYCIN;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL DEATH; CELL GROWTH; CELL VIABILITY; CHEMOLUMINESCENCE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE MICROSCOPY; MTT ASSAY; RADIOSENSITIVITY; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

AUTOPHAGY; CHEMOTHERAPY; EPIDERMAL GROWTH FACTOR RECEPTOR; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; RADIOTHERAPY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; AUTOPHAGY; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; ESOPHAGEAL NEOPLASMS; HUMANS; RADIATION TOLERANCE; X-RAYS;

EID: 84899700630     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370214525315     Document Type: Article

References (28)

1. Jemal A.Global cancer statistics.CA Cancer J Clin. 2011;61:134-134.
2. Park BB,Im YH,Hwang IG,Lee SC,Ahn JS,Ahn MJ,Lim HY,Kang WK,Park K.Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma.Invest New Drugs. 2008;26:387-92.
3. Jin J,Xu X,Wang F,Yan G,Liu J,Lu W,Li X,Tucker SJ,Zhong B,Cao Z,Wang D.Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.J Thorac Oncol. 2009;4:1017-21.
4. Tepper J,Krasna MJ,Niedzwiecki D,Hollis D,Reed CE,Goldberg R,Kiel K,Willett C,Sugarbaker D,Mayer R.Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.J Clin Oncol. 2008;26:1086-92.
5. Gibault L,Metges JP,Conan-Charlet V,Lozac'h P,Robaszkiewicz M,Bessaguet C,Lagarde N,Volant A.Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer.Br J Cancer. 2005;93:107-15.
6. Wilkinson NW,Black JD,Roukhadze E,Driscoll D,Smiley S,Hoshi H,Geradts J,Javle M,Brattain M.Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma.J Gastrointest Surg. 2004;8:448-53.
7. Rosell R,Vergnenegre A,Liu B,Cobo M,Massuti B,Wei J,Molina MA,Costa C,Queralt C,Taron M.Biomarkers in lung oncology.Pulm Pharmacol Ther. 2010;23:508-14.
8. Chakravarti A,Winter K,Wu CL,Kaufman D,Hammond E,Parliament M,Tester W,Hagan M,Grignon D,Heney N,Pollack A,Sandler H,Shipley W.Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the Radiation Therapy Oncology Group.Int J Radiat Oncol Biol Phys. 2005;62:309-17.
9. Vordermark D,Kolbl O.Lack of survival benefit after stereotactic radiosurgery boost for glioblastoma multiforme: Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of radiation therapy oncology group 93-05 protocol: In regard to Souhami et al.Int J Radiat Oncol Biol Phys. 2005;62:296-7.
10. Yang Z,Klionsky DJ.Eaten alive: A history of macroautophagy.Nat Cell Biol. 2010;12:814-22.
11. Levine B,Kroemer G.Autophagy in aging, disease and death: the true identity of a cell death impostor.Cell Death Differ. 2009;16:1-2.
12. Talavera A,Friemann R,Gomez-Puerta S,Martinez-Fleites C,Garrido G,Rabasa A,Lopez-Requena A,Pupo A,Johansen RF,Sanchez O,Krengel U,Moreno E.Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.Cancer Res. 2009;69:5851-9.
13. Crombet T,Osorio M,Cruz T,Roca C,del Castillo R,Mon R,Iznaga-Escobar N,Figueredo R,Koropatnick J,Renginfo E,Fernandez E,Alvarez D,Torres O,Leonard I,Perez R,Lage A.Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.J Clin Oncol. 2004;22:1646-54.
14. Ramos TC,Figueredo J,Catala M,Gonzalez S,Selva JC,Cruz TM,Toledo C,Silva S,Pestano Y,Ramos M,Leonard I,Torres O,Marinello P,Perez R,Lage A.Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial.Cancer Biol Ther. 2006;5:375-9.
15. Huang Y,Yu T,Fu X,Chen J,Liu Y,Li C,Xia Y,Zhang Z,Li L.EGFR inhibition prevents in vitro tumor growth of salivary adenoid cystic carcinoma.BMC Cell Biol. 2013;14:13-13.
16. Zhao L,Li QQ,Zhang R,Xi M,Liao YJ,Qian D,He LR,Zeng YX,Xie D,Liu MZ.The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin.Tumour Biol. 2012;33:1115-23.
17. Slee EA,Zhu H,Chow SC,MacFarlane M,Nicholson DW,Cohen GM.Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD.FMK) inhibits apoptosis by blocking the processing of CPP32.Biochem J. 1996;315:21-4.
18. Jin S,White E.Role of autophagy in cancer: management of metabolic stress.Autophagy. 2007;3:28-31.
19. Das AK,Chen BP,Story MD,Sato M,Minna JD,Chen DJ,Nirodi CS.Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma.Cancer Res. 2007;67:5267-74.
20. Fung C,Chen X,Grandis JR,Duvvuri U.EGFR tyrosine kinase inhibition induces autophagy in cancer cells.Cancer Biol Ther. 2012;13:1417-24.
21. Li X,Lu Y,Pan T,Fan Z.Roles of autophagy in cetuximab-mediated cancer therapy against EGFR.Autophagy. 2010;6:1066-77.
22. Diaz Miqueli A,Rolff J,Lemm M,Fichtner I,Perez R,Montero E.Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies.Br J Cancer. 2009;100:950-8.
23. Akashi Y,Okamoto I,Iwasa T,Yoshida T,Suzuki M,Hatashita E,Yamada Y,Satoh T,Fukuoka M,Ono K,Nakagawa K.Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status.Br J Cancer. 2008;98:749-55.
24. Garrido G,Tikhomirov IA,Rabasa A,Yang E,Gracia E,Iznaga N,Fernandez LE,Crombet T,Kerbel RS,Perez R.Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile.Cancer Biol Ther. 2011;11:373-82.
25. Chu Q,Amano O,Kanda Y,Kunii S,Wang Q,Sakagami H.Tumor-specific cytotoxicity and type of cell death induced by gefitinib in oral squamous cell carcinoma cell lines.Anticancer Res. 2009;29:5023-31.
26. Li X,Luwor R,Lu Y,Liang K,Fan Z.Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells.Oncogene. 2006;25:525-35.
27. Lu Y,Li X,Liang K,Luwor R,Siddik ZH,Mills GB,Mendelsohn J,Fan Z.Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.Cancer Res. 2007;67:8240-7.
28. Li X,Fan Z.The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.Cancer Res. 2010;70:5942-52.